gracecastuc-038_lung_managing acq. resistance to egfr therapy (and probably crizotinib, too)
Published 11 years ago • 48 plays • Length 5:34Download video MP4
Download video MP3
Similar videos
-
28:22
gracecast-088_lung-cancer_challenging cases in lung cancer: acquired resistance to egfr tki therapy
-
1:45
gracecastuc-034_lung_management strategies for acquired resistance to targeted therapies
-
3:22
acquired resistance in lung cancer treatment - lcvl 2024
-
1:59:57
grace - global resource for advancing cancer education live stream
-
3:07
third generation egfr tkis for acquired resistance
-
8:46
grace targeted therapies in lung cancer 2021 - liquid and tissue biopsies in acquired resistance
-
2:25
gracecastuc-075_lung_recommending a repeat biopsy with acqd. resistance to targeted therapy
-
14:43
gracecast-070_lung-cancer_q&a for acquired egfr tki and re-biopsying
-
7:24
gracecastuc-025_lung_dr. riely on approach for acq. resistance to targeted therapies in adv. nsclc
-
5:09
gracecastuc-013_lung_what should we do for a "mixed response" to lung cancer treatment?
-
3:02
resistance mechanisms in egfr nsclc treatment - targeted therapies in lung cancer 2023
-
2:30
acquired resistance to osimertinib in egfr nsclc - 2022 program: targeted therapies forum - english
-
29:24
gracecast-068_lung-cancer_sequist on acquired resistance to egfr
-
13:40
gracecast-104_lung-cancer_immunotherapy for lung cancer: q and a session
-
2:10
slcvl raez #17 treatment options for acquired resistance to egfr tkis: t790m-negative disease
-
2:05
grace targeted therapies lung cancer 2021 - bypass mechanisms (pik3, mek, erk, etc)
-
1:59
gracecastuc-052_lung_juergens on managing acquired resistance to targeted therapies for adv. nsclc
-
21:33
optimal ngs platforms, how to interpret - grace targeted therapies in lung cancer patient forum 2021
-
4:40
ntrk nsclc: treatment options and side effects - targeted therapies in lung cancer 2023